Sugi Predict

Sugi Predict / Compounds / SCHEMBL7184615

SCHEMBL7184615

SCHEMBL7184615

COCCOc1ccccc1PC(=O)c1c(OC)cc(OC)cc1OC.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.40
▸ LMNA P02545 5/20 0.40
▸ L3MBTL1 Q9Y468 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ ATM Q13315 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ HTT P42858 2/20 0.37
▸ ABCG2 Q9UNQ0 2/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177491 0.89 L3MBTL1 (0.43) MAPTL3MBTL1SMN1; SMN2KMT2ATSHR
SCHEMBL7181169 0.89 L3MBTL1 (0.38) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7189896 0.88 KMT2A (0.42) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7187428 0.88 TSHR (0.46) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7182802 0.85 HTT (0.40) MAPTL3MBTL1KMT2AALDH1A1POLB
SCHEMBL7184610 0.84 MAPT (0.41) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7187396 0.84 LMNA (0.46) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7181649 0.82 MAPT (0.44) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7182404 0.81 CYP3A4 (0.39) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL7186863 0.81 KMT2A (0.41) MAPTLMNAL3MBTL1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885LMNA 3241/4885L3MBTL1 302/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885LMNA 3247/4885L3MBTL1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.